Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Talking gene therapy with Bluebird Bio’s head of Europe

Bluebird bio is a US biotechnology company primarily focused on ex vivo gene therapy solutions, but with recent progression into immunotherapy and gene editing fields. Its successful combination of innovative technology and business model got it noticed by the MIT Technology Review, which listed it as one of its 50 Smartest Companies in 2017. We spoke to Bluebird Bio’s senior vice-president and head of Europe Andrew Obenshain about the company’s current work and its future plans.


Go Top